AstraZeneca Presents Imfinzi (durvalumab) Plus tremelimumab Combination Data at AACR Annual Meeting

Phase Ib Study 006 long-term follow-up shows clinical activity in PD-L1 ≥25% and <25% groups in 2nd-line non-small cell lung cancer
Phase I Study 10 data shows clinical activity with combination treatment in 2nd-line metastatic urothelial carcinom…